Wang et al. recently demonstrated that pharmacologically inhibiting oxidative phosphorylation with NG52 (an inhibitor of phosphoglycerate kinase 1) reduces glioma proliferation both in vitro and in vivo. Here, PGK1 is linked to glioma.